# ENZARAD (NCT02446444)

> Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02446444
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Sydney
- Conditions: Prostatic Neoplasms
- Interventions: Enzalutamide; Conventional NSAA; LHRHA; External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
- Enrollment: 802
- Primary outcome: Metastasis-free survival

## Commentary we found

- X threads: 65
- YouTube: 29
- Podcasts: 21

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=enzarad-nct02446444

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02446444", "email": "<work email>"}; the inbox owner confirms by the emailed link.